Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands.
CancerSpectrum Knowledge Environment (Impact Factor: 15.16). 11/2004; 96(21):1585-92. DOI: 10.1093/jnci/djh298
Source: PubMed

ABSTRACT Irinotecan is a topoisomerase I inhibitor that has been approved for use as a first- and second-line treatment for colorectal cancer. The response to irinotecan is variable, possibly because of interindividual variation in the expression of the enzymes that metabolize irinotecan, including cytochrome P450 3A4 (CYP3A4) and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). We prospectively explored the relationships between CYP3A phenotype, as assessed by erythromycin metabolism and midazolam clearance, and the metabolism of irinotecan and its active metabolite SN-38.
Of the 30 white cancer patients, 27 received at least two treatments with irinotecan administered as one 90-minute infusion (dose, 600 mg) with 3 weeks between treatments, and three received only one treatment. Before the first and second treatments, patients underwent an erythromycin breath test and a midazolam clearance test as phenotyping probes for CYP3A4. Erythromycin metabolism was assessed as the area under the curve for the flux of radioactivity in exhaled CO2 within 40 minutes after administration of [N-methyl-14C]erythromycin. Midazolam and irinotecan were measured by high-performance liquid chromatography. Genomic DNA was isolated from blood and screened for genetic variants in CYP3A4 and UGT1A1. All statistical tests were two-sided.
CYP3A4 activity varied sevenfold (range = 0.223%-1.53% of dose) among patients, whereas midazolam clearance varied fourfold (range = 262-1012 mL/min), although intraindividual variation was small. Erythromycin metabolism was not statistically significantly associated with irinotecan clearance (P = .090), whereas midazolam clearance was highly correlated with irinotecan clearance (r = .745, P<.001). In addition, the presence of a UGT1A1 variant with a (TA)7 repeat in the promoter (UGT1A1*28) was associated with increased exposure to SN-38 (435 ng x h/mL, 95% confidence interval [CI] = 339 to 531 ng x h/mL in patients who are homozygous for wild-type UGT1A1; 631 ng x h/mL, 95% CI = 499 to 762 ng . h/mL in heterozygous patients; and 1343 ng x h/mL, 95% CI = 0 to 4181 ng x h/mL in patients who are homozygous for UGT1A1*28) (P = .006).
CYP3A4 phenotype, as assessed by midazolam clearance, is statistically significantly associated with irinotecan pharmacokinetics. Evaluation of midazolam clearance combined with UGT1A1*28 genotyping may assist with optimization of irinotecan chemotherapy.


Available from: Alex Sparreboom, May 30, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:Treatment of advanced and metastatic colorectal cancer with irinotecan is hampered by severe toxicities. The active metabolite of irinotecan, SN-38, is a known substrate of drug-metabolising enzymes, including UGT1A1, as well as OATP and ABC drug transporters.Methods:Blood samples (n=127) and tumour tissue (n=30) were obtained from advanced cancer patients treated with irinotecan-based regimens for pharmacogenetic and drug level analysis and transporter expression. Clinical variables, toxicity, and outcomes data were collected.Results:SLCO1B1 521C was significantly associated with increased SN-38 exposure (P<0.001), which was additive with UGT1A1*28. ABCC5 (rs562) carriers had significantly reduced SN-38 glucuronide and APC metabolite levels. Reduced risk of neutropenia and diarrhoea was associated with ABCC2-24C/T (odds ratio (OR)=0.22, 0.06-0.85) and CES1 (rs2244613; OR=0.29, 0.09-0.89), respectively. Progression-free survival (PFS) was significantly longer in SLCO1B1 388G/G patients and reduced in ABCC2-24T/T and UGT1A1*28 carriers. Notably, higher OATP1B3 tumour expression was associated with reduced PFS.Conclusions:Clarifying the association of host genetic variation in OATP and ABC transporters to SN-38 exposure, toxicity and PFS provides rationale for personalising irinotecan-based chemotherapy. Our findings suggest that OATP polymorphisms and expression in tumour tissue may serve as important new biomarkers.British Journal of Cancer Advance online publication, 22 January 2015; doi:10.1038/bjc.2015.5
    British Journal of Cancer 01/2015; 112(5). DOI:10.1038/bjc.2015.5 · 4.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective We aimed to establish a method to assess systemic and pre-systemic cytochrome P450 (CYP) 3A activity using ineffective microgram doses of midazolam.Methods In an open, one-sequence, cross-over study, sixteen healthy participants received intravenous and oral midazolam at microgram (0.001 mg intravenous and 0.003 mg oral) and at regular milligram (1 mg intravenous and 3 mg oral) doses to assess the linearity of plasma and urine pharmacokinetics.ResultsDose-normalised AUC and Cmax were 37.1 h*ng/ml [95%-CI: 35.5–40.6] and 39.1 ng/ml [30.4–50.2] for the microdose and 39.0 h*ng/ml [36.1–42.1] and 37.1 ng/ml [26.9–51.3] for the milligram dose. Clmet was 253 ml/min [201–318] vs. 278 ml/min [248–311] for i.v. doses and 1880 ml/min [1590-2230] vs. 2050 ml/min [1720 – 2450] for oral doses. Oral bioavailability of a midazolam microdose was 23.4% [20.0–27.3] vs. 20.9% [17.1–25.5] after the regular dose. Hepatic and gut extraction ratios for microgram doses were 0.44 [0.39–0.49] and 0.53 [0.45–0.63] and compared well with those for milligram doses (0.43 [0.37–0.49] and 0.61 [0.53–0.70]).Conclusion The pharmacokinetics of an intravenous midazolam microdose is linear to the applied regular doses and can be used to safely assess systemic CYP3A activity and, in combination with oral microdoses, pre-systemic CYP3A activity.
    British Journal of Clinical Pharmacology 09/2014; 79(2). DOI:10.1111/bcp.12502 · 3.69 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: During the past two decades the first sequencing of the human genome was performed showing its high degree of inter-individual differentiation, as a result of large international research projects (Human Genome Project, the 1000 Genomes Project International Hap- Map Project, and Programs for Genomic Applications NHLBI-PGA). This period was also a time of intensive development of molecular biology techniques and enormous knowledge growth in the biology of cancer. For clinical use in the treatment of patients with colorectal cancer (CRC), in addition to fluoropyrimidines, another two new cytostatic drugs were allowed: irinotecan and oxaliplatin. Intensive research into new treatment regimens and a new generation of drugs used in targeted therapy has also been conducted. The last 20 years was a time of numerous in vitro and in vivo studies on the molecular basis of drug resistance. One of the most important factors limiting the effectiveness of chemotherapy is the primary and secondary resistance of cancer cells. Understanding the genetic factors and mechanisms that contribute to the lack of or low sensitivity of tumour tissue to cytostatics is a key element in the currently developing trend of personalized medicine. Scientists hope to increase the percentage of positive treatment response in CRC patients due to practical applications of pharmacogenetics/pharmacogenomics. Over the past 20 years the clinical usability of different predictive markers has been tested among which only a few have been confirmed to have high application potential. This review is a synthetic presentation of drug resistance in the context of CRC patient chemotherapy. The multifactorial nature and volume of the issues involved do not allow the author to present a comprehensive study on this subject in one review.
    World Journal of Gastroenterology 08/2014; 20(29):9775-9827. DOI:10.3748/wjg.v20.i29.9775 · 2.43 Impact Factor